ZZ BIOTECH NEWS
ZZ BIOTECH PRESS ROOM
Welcome to our Online Press Room
At ZZ Biotech, not only are we known for providing rich content and value information to our audiences, we are also known for providing easy answers for the news media.
If you’re a member of the news media and working on deadline where we can assist you, please contact our media relations representative via email. We will respond to all media requests within a 24-hour period.
Media Contact
Leigh Fazzina
EVC Group
leigh@evcgroup.com
Press Releases
Listed below in chronological order are our news announcements. If you require further assistance with obtaining information contained in one of the announcements, please call our media contact.
Experimental stroke therapeutic developed at Keck Medicine of USC also shows promise for people with Lou Gehrig’s disease (ALS)
New research finds vascular damage in mice with ALS contributes to early development of the neurodegenerative disease, while repairing damage delays disease progression LOS ANGELES,
Experimental drug reduces brain damage, eliminates brain hemorrhaging in rodents afflicted by stroke
Multi-site phase 2 clinical trials anticipated to begin recruiting patients in 2014 LOS ANGELES, October 24, 2013 — An experimental drug called 3K3A-APC appears to
Clinical Trials Start for Stroke Drug Developed by Scripps Research Institute, USC, and ZZ Biotech
Experimental drug may extend window for effective stroke treatment LA JOLLA, CA, August 8, 2012 — Clinical trials start this week for a stroke drug
ZZ Biotech Initiates Phase 1 Study with 3K3A-APC for the Treatment of Acute Ischemic Stroke
HOUSTON, Texas, August 8, 2012—ZZ Biotech, LLC today announced that it has commenced dosing healthy volunteers in a Phase 1 clinical study with 3K3A-APC, a
Experimental Drug May Extend Therapeutic Window for Stroke
Clinical safety trials in humans to start this summer LOS ANGELES, July 17, 2012 — A team led by a physician-scientist at the University of